Literature DB >> 22761217

Disappearance of pituitary macro adenoma with combination of ketoconazole and cabergoline treatment: an unusual case of Cushing's syndrome with interesting findings.

Asma Ahmed1, Saira Furqan, Najmul Islam.   

Abstract

Cushing syndrome is associated with significant morbidity and mortality if left untreated because of associated metabolic and cardiovascular complications. An extremely ill patient with Cushing's syndrome caused by adrenocorticotropic hormone producing pituitary macro adenoma responded dramatically to ketoconazole and cabergoline treatment. His 4 month long medical treatment resulted in improvement of hypercotisolism clinically and biochemically and in complete disappearance of pituitary macro adenoma without any surgical intervention.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22761217      PMCID: PMC3391398          DOI: 10.1136/bcr.03.2012.6025

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  12 in total

1.  Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease.

Authors:  Richard A Feelders; Christiaan de Bruin; Alberto M Pereira; Johannes A Romijn; Romana T Netea-Maier; Ad R Hermus; Pierre M Zelissen; Ramona van Heerebeek; Frank H de Jong; Aart-Jan van der Lely; Wouter W de Herder; Leo J Hofland; Steven W Lamberts
Journal:  N Engl J Med       Date:  2010-05-13       Impact factor: 91.245

2.  The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline.

Authors:  Lynnette K Nieman; Beverly M K Biller; James W Findling; John Newell-Price; Martin O Savage; Paul M Stewart; Victor M Montori
Journal:  J Clin Endocrinol Metab       Date:  2008-03-11       Impact factor: 5.958

Review 3.  [Treatment of Cushing's disease. Transsphenoidal surgery and pituitary radiotherapy].

Authors:  Cristina Lamas Oliveira; Javier Estrada García
Journal:  Endocrinol Nutr       Date:  2009-05-18

4.  Complete remission of Nelson's syndrome after 1-year treatment with cabergoline.

Authors:  R Pivonello; A Faggiano; F Di Salle; M Filippella; G Lombardi; A Colao
Journal:  J Endocrinol Invest       Date:  1999-12       Impact factor: 4.256

5.  Nelson's syndrome: complete remission with cabergoline but not with bromocriptine or cyproheptadine treatment.

Authors:  Luiz Augusto Casulari; Luciana A Naves; Paulo A Mello; Aldo Pereira Neto; Carla Papadia
Journal:  Horm Res       Date:  2004-11-19

Review 6.  Pitfalls in the diagnosis of Cushing's syndrome.

Authors:  Lucio Vilar; Maria da Conceição Freitas; Manuel Faria; Renan Montenegro; Luiz Augusto Casulari; Luciana Naves; Oscar D Bruno
Journal:  Arq Bras Endocrinol Metabol       Date:  2007-11

Review 7.  Drugs in the medical treatment of Cushing's syndrome.

Authors:  David E Schteingart
Journal:  Expert Opin Emerg Drugs       Date:  2009-12       Impact factor: 4.191

Review 8.  Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement.

Authors:  B M K Biller; A B Grossman; P M Stewart; S Melmed; X Bertagna; J Bertherat; M Buchfelder; A Colao; A R Hermus; L J Hofland; A Klibanski; A Lacroix; J R Lindsay; J Newell-Price; L K Nieman; S Petersenn; N Sonino; G K Stalla; B Swearingen; M L Vance; J A H Wass; M Boscaro
Journal:  J Clin Endocrinol Metab       Date:  2008-04-15       Impact factor: 5.958

Review 9.  Cushing's Syndrome.

Authors:  Rosario Pivonello; Maria Cristina De Martino; Monica De Leo; Gaetano Lombardi; Annamaria Colao
Journal:  Endocrinol Metab Clin North Am       Date:  2008-03       Impact factor: 4.741

10.  Gamma knife radiosurgery in the treatment of Cushing disease: long-term results.

Authors:  Tatsuya Kobayashi; Yoshihisa Kida; Yoshimasa Mori
Journal:  J Neurosurg       Date:  2002-12       Impact factor: 5.115

View more
  3 in total

Review 1.  Pituitary-directed medical therapy in Cushing's disease.

Authors:  Stephan Petersenn; Maria Fleseriu
Journal:  Pituitary       Date:  2015-04       Impact factor: 4.107

Review 2.  The Treatment of Cushing's Disease.

Authors:  Rosario Pivonello; Monica De Leo; Alessia Cozzolino; Annamaria Colao
Journal:  Endocr Rev       Date:  2015-06-11       Impact factor: 19.871

Review 3.  The dopaminergic control of Cushing's syndrome.

Authors:  R Pivonello; C Pivonello; C Simeoli; M C De Martino; A Colao
Journal:  J Endocrinol Invest       Date:  2022-04-23       Impact factor: 5.467

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.